Haemophilus influenzae type b conjugate vaccine

S. A. Plotkin; R. S. Daum; G. S. Giebink; C. B. Hall; M. Lepow; E. K. Marcuse; G. H. McCracken; C. F. Phillips; G. B. Scott; H. T. Wright; G. Peter; A. R. Hinman; P. Parkman; R. Gold; J. G. Easton

Haemophilus influenzae type b conjugate vaccine

S. A. Plotkin, R. S. Daum, G. S. Giebink, C. B. Hall, M. Lepow, E. K. Marcuse, G. H. McCracken, C. F. Phillips, G. B. Scott, H. T. Wright, G. Peter, A. R. Hinman, P. Parkman, R. Gold, J. G. Easton

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

On Dec 22, 1987, the first conjugate vaccine was licensed by the FDA for the prevention of infections due to Haemophilus influenzae type b. This vaccine is a conjugate of H influenzae type b capsular polysaccharide and diphtheria toxoid and is officially designated as Haemophilus b conjugate vaccine (diphtheria toxoid-conjugate). The purpose of this statement is to provide background information, perspective, and recommendations for the use of this product.

Original language	English (US)
Pages (from-to)	908-911
Number of pages	4
Journal	Pediatrics
Volume	81
Issue number	6
State	Published - 1988

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Cite this

@article{c8ff816ef74c41fda703fea19414582b,

title = "Haemophilus influenzae type b conjugate vaccine",

abstract = "On Dec 22, 1987, the first conjugate vaccine was licensed by the FDA for the prevention of infections due to Haemophilus influenzae type b. This vaccine is a conjugate of H influenzae type b capsular polysaccharide and diphtheria toxoid and is officially designated as Haemophilus b conjugate vaccine (diphtheria toxoid-conjugate). The purpose of this statement is to provide background information, perspective, and recommendations for the use of this product.",

author = "Plotkin, {S. A.} and Daum, {R. S.} and Giebink, {G. S.} and Hall, {C. B.} and M. Lepow and Marcuse, {E. K.} and McCracken, {G. H.} and Phillips, {C. F.} and Scott, {G. B.} and Wright, {H. T.} and G. Peter and Hinman, {A. R.} and P. Parkman and R. Gold and Easton, {J. G.}",

year = "1988",

language = "English (US)",

volume = "81",

pages = "908--911",

journal = "Pediatrics",

issn = "0031-4005",

publisher = "American Academy of Pediatrics",

number = "6",

}

TY - JOUR

T1 - Haemophilus influenzae type b conjugate vaccine

AU - Plotkin, S. A.

AU - Daum, R. S.

AU - Giebink, G. S.

AU - Hall, C. B.

AU - Lepow, M.

AU - Marcuse, E. K.

AU - McCracken, G. H.

AU - Phillips, C. F.

AU - Scott, G. B.

AU - Wright, H. T.

AU - Peter, G.

AU - Hinman, A. R.

AU - Parkman, P.

AU - Gold, R.

AU - Easton, J. G.

PY - 1988

Y1 - 1988

N2 - On Dec 22, 1987, the first conjugate vaccine was licensed by the FDA for the prevention of infections due to Haemophilus influenzae type b. This vaccine is a conjugate of H influenzae type b capsular polysaccharide and diphtheria toxoid and is officially designated as Haemophilus b conjugate vaccine (diphtheria toxoid-conjugate). The purpose of this statement is to provide background information, perspective, and recommendations for the use of this product.

AB - On Dec 22, 1987, the first conjugate vaccine was licensed by the FDA for the prevention of infections due to Haemophilus influenzae type b. This vaccine is a conjugate of H influenzae type b capsular polysaccharide and diphtheria toxoid and is officially designated as Haemophilus b conjugate vaccine (diphtheria toxoid-conjugate). The purpose of this statement is to provide background information, perspective, and recommendations for the use of this product.

UR - http://www.scopus.com/inward/record.url?scp=0023879659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023879659&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023879659

SN - 0031-4005

VL - 81

SP - 908

EP - 911

JO - Pediatrics

JF - Pediatrics

IS - 6

ER -

Haemophilus influenzae type b conjugate vaccine

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this